Related Experiment Video

Updated: Nov 28, 2025

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

14.1K

CDK4/6 and MAPK-Crosstalk as Opportunity for Cancer Treatment

Lisa Scheiblecker1, Karoline Kollmann1, Veronika Sexl1

  • 1Institute of Pharmacology and Toxicology, University of Veterinary Medicine Vienna, 1210 Vienna, Austria.

Pharmaceuticals (Basel, Switzerland)
|December 1, 2020
PubMed

Insights

Cancer treatment requires new strategies due to resistance. Combining targeted therapies, like those inhibiting cyclin-dependent kinase 6 (CDK6) and the MAPK pathway, shows promise for overcoming this challenge.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • Cancer remains a significant global health challenge, often developing resistance to existing targeted therapies and inhibitors.
  • Protein kinases are crucial signaling regulators frequently dysregulated in cancer, representing key therapeutic targets.
  • The urgent need for alternative treatment options necessitates exploring novel therapeutic strategies, including drug combinations.

Purpose of the Study:

  • To investigate the interplay between the cell cycle kinase CDK6 and the MAPK pathway in cancer.
  • To provide an overview of clinical studies evaluating combination treatments involving CDK6 and MAPK pathway inhibitors.
  • To highlight the potential of drug combinations as a strategy to overcome cancer resistance.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of the roles of CDK6 and the MAPK pathway in cancer signaling.
  • Synthesis of data from clinical trials investigating combination therapies.

Main Results:

  • CDK6 and the MAPK pathway are frequently implicated in cancer development and progression.
  • Combinational targeting of CDK6 and MAPK pathway components demonstrates potential in preclinical models.
  • Clinical studies are exploring various combinations for diverse cancer types, with preliminary data suggesting efficacy.

Conclusions:

  • Targeting CDK6 and the MAPK pathway, particularly in combination, offers a promising avenue for overcoming cancer treatment resistance.
  • Further clinical investigation is warranted to optimize drug combinations and establish their role in cancer therapy.
  • Drug combinations represent a vital strategy to address the limitations of monotherapies in combating cancer.
Keywords:
CDK6MAPKcancercombinationalinhibitorsp38palbociclib

More Related Videos

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics06:00

Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics

Published on: May 14, 2016

11.3K
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.6K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.4K
M-Cdk Drives Transition Into Mitosis02:15

M-Cdk Drives Transition Into Mitosis

Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
6.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.2K